Effectiveness of infliximab in Brazilian children and adolescents with crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue 6, 2010, Pages 628-633

  Tiemi, Juliana ^a   Komati, Saito ^a   Sdepanian, Vera Lucia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adolescent; Biological therapy; Child; Crohn disease; Pediatrics; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HUMAN; LIGHTIGER COLITIS ACTIVITY INDEX; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BRAZIL; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFANT; MALE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77953130737     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181bbf481     Document Type: Article

References (34)

1. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Molec Immunol 1993;30:1443-53.
2. Derkx B, Taminiau J, Radema S, et al. Tumor-necrosis-factor-antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
3. Targan SR, Hanauer SB, van Deventer S J H, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405. (Pubitemid 29205403)
5. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al., ACCENT I Study Group Maintenance infliximab for Crohn's disease: the accent I randomized trial. Lancet 2002;359:1541-9.
7. D'Haens G, van Deventer S, Hogezand RV, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
8. van Dullemen HM, van Deventer S J H, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
9. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
10. Su C, Zalzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-84.
11. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
12. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
13. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
14. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
15. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
16. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7.
17. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31.
18. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004;39:46-52.
19. Cezard J-P, Nouaili N, Talbotec C, et al. A prospective study of efficacy and tolerance of a chimeric antibody to tumor necrosis factor (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632-6.
20. Lamireau T, Cézard J-P, Dabalie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004;10:745-50.
21. Hyams J, Crandall W, Kugathasan S, et al., REACH Study Group-Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
22. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
23. Wewer V, Riis L, Husby S, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:40-5.
24. Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213-8.
25. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002;34:307-11.
26. Mamula P, Markowitz JM, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298-301.
27. Russel GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39:166-70.
28. de Ridder L, Benninga MA, Taminiau JA, et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14.
29. Kinney T, Rawlins M, Kozarek R, et al. Immunomodulators and"on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003;98:608-12.
30. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
31. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
32. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
33. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
34. Zaltman C. Inflammatory bowel disease: how relevant for Brazil? Cad Saude Publica 2007;23:992-3.